Panelists from Genovac, will present case studies of how they have leveraged their core genetic immunization technology and the Beacon optofluidic system to rapidly discover antibodies against challenging targets, such as GPCRs, from a variety of different animal species.
Find out how the Opto Plasma B Discovery workflow simplifies and dramatically reduces the time needed to down-select potential lead candidates, even for difficult membrane proteins.
Berkeley Lights and ChemPartner provide a case study in accelerated discovery of unique Anti-PD-L1 antibodies from spleen versus bone marrow of immunized mice, via single plasma B cell cloning on the Beacon platform.
Learn how we enable lead candidate down-selection in 1 day by performing functional characterization during primary screening. Case studies highlight how our customers are dramatically accelerating development of next-generation antibody therapeutics.